The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation.

The approval applies to use of larotrectinib (Vitrakvi; Bayer, Loxo Oncology) for patients who have metastatic disease or for whom surgical resection likely will result in severe morbidity, and who either progressed after treatment or have no satisfactory alternative treatments.